The Neuroimmune Pharmacology of SARS-CoV-2

Santosh Kumar, Sowmya Yelamanchili, Pankaj Seth, Jean M. Bidlack, Gurudutt Pendyala, Sanjay Maggirwar, Sulie L. Chang

Research output: Contribution to journalComment/debatepeer-review


This guest commentary introduces “The Neuroimmune Pharmacology of SARS-CoV-2,” a special theme issue for The Journal of Neuroimmune Pharmacology led by the Society on NeuroImmune Pharmacology. The issue builds on the Society’s Virtual Workshop on COVID-19 held April 9, 2021. Graphical abstract: Top row from left: Drs. Santosh Kumar, Sowmya Yelamanchili, Pankaj Seth, Jean M. Bidlack; Bottom row from left: Drs. Gurudutt Pendyala, Sanjay Maggirwar, and Sulie L. Chang.[Figure not available: see fulltext.].

Original languageEnglish (US)
Pages (from-to)699-705
Number of pages7
JournalJournal of Neuroimmune Pharmacology
Issue number4
StatePublished - Dec 2021


  • COVID-19
  • Diversity
  • Early-career investigators
  • Equity and inclusion
  • Neuroimmune pharmacology
  • Oral history
  • SARS-CoV-2
  • Therapeutics
  • Vaccines
  • Well-being

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology and Allergy
  • Immunology
  • Pharmacology


Dive into the research topics of 'The Neuroimmune Pharmacology of SARS-CoV-2'. Together they form a unique fingerprint.

Cite this